These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells. Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM Front Immunol; 2021; 12():641521. PubMed ID: 33796107 [TBL] [Abstract][Full Text] [Related]
4. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ MAbs; 2015; 7(3):494-504. PubMed ID: 25933349 [TBL] [Abstract][Full Text] [Related]
5. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428 [TBL] [Abstract][Full Text] [Related]
6. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548 [TBL] [Abstract][Full Text] [Related]
7. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567 [TBL] [Abstract][Full Text] [Related]
10. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644 [TBL] [Abstract][Full Text] [Related]
11. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Schirrmann T; Pecher G Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266 [TBL] [Abstract][Full Text] [Related]
12. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001 [TBL] [Abstract][Full Text] [Related]
13. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia. Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633 [TBL] [Abstract][Full Text] [Related]
14. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R; Kössl C; Bucci D; Lucas DM; Yu J; Caligiuri MA; Blum W; Adam PJ; Borges E; Rueter B; Heider KH; Marcucci G; Muthusamy N Blood; 2016 Jun; 127(23):2879-89. PubMed ID: 27013443 [TBL] [Abstract][Full Text] [Related]
15. Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement. Vankemmelbeke M; McIntosh RS; Chua JX; Kirk T; Daniels I; Patsalidou M; Moss R; Parsons T; Scott D; Harris G; Ramage JM; Spendlove I; Durrant LG Cancer Res; 2020 Aug; 80(16):3399-3412. PubMed ID: 32532823 [TBL] [Abstract][Full Text] [Related]
16. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing. Perl A; Looney RJ; Ryan DH; Abraham GN J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P MAbs; 2015; 7(4):743-51. PubMed ID: 25970007 [TBL] [Abstract][Full Text] [Related]
18. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158 [TBL] [Abstract][Full Text] [Related]